-
Study aim
-
The effect of Pentoxifylline in improving myocardial damage in ST-segment elevation myocardial infarction patients treated with primary angioplasty is determined.
-
Design
-
Clinical trial with a control group, with parallel groups, double-blind, randomized, phase 3 on 70 patients. For randomization, the sequence of random numbers prepared with SPSS software was used.
-
Settings and conduct
-
The current study is a double-blind clinical trial that was conducted in the CCU department of Baqiyatullah Azam Hospital on 70 patients. After obtaining informed consent from the patients, the available patients were checked in terms of the entry criteria and were assigned to two control and intervention groups using white and black cards sorted based on the sequence of randomization. Then Pentoxifylline was used in the intervention group, and placebo was used in the control group.
-
Participants/Inclusion and exclusion criteria
-
Patients with myocardial infarction with ST segment elevation who refer to Baqiyatullah Hospital in Tehran and are candidates for percutaneous coronary interventions, with criteria: chest pain for more than 30 minutes and less than 12 hours with ST segment elevation at the point J in ECG for more than 1 mm in at least two consecutive leads, successful PCI, sinus rhythm and informed consent to participate in the study are included.
-
Intervention groups
-
receiving pentoxifylline drug; Three 400 mg tablets, generic form, immediately before treatment with percutaneous coronary interventions
-
Main outcome variables
-
In this study, the effect of Pentoxifylline drug on cardiac isozymes, including Troponin I, Creatine Phosphokinase, C-reactive protein and interleukin-6, was measured in order to investigate the recovery of myocardial damage.